Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) PT at $27.29

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Rating) have been given a consensus rating of “Buy” by the nine research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $27.29.

A number of equities research analysts recently weighed in on the company. Brookline Capital Acquisition assumed coverage on Caribou Biosciences in a research note on Monday, February 14th. They issued a “buy” rating and a $19.00 price target on the stock. Royal Bank of Canada assumed coverage on Caribou Biosciences in a research note on Thursday, February 17th. They issued an “outperform” rating and a $22.00 price target on the stock. Brookline Capital Management restated a “buy” rating on shares of Caribou Biosciences in a research note on Monday, February 14th. SVB Leerink decreased their price objective on Caribou Biosciences from $32.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, March 22nd. Finally, Zacks Investment Research raised Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 12th.

Shares of Caribou Biosciences stock opened at $7.40 on Friday. Caribou Biosciences has a 12-month low of $7.04 and a 12-month high of $32.65. The business’s 50 day moving average is $8.85 and its 200-day moving average is $13.52.

Caribou Biosciences (NASDAQ:CRBU – Get Rating) last posted its quarterly earnings results on Monday, March 21st. The company reported ($0.34) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.34). The business had revenue of $2.56 million during the quarter, compared to the consensus estimate of $5.27 million. As a group, equities analysts expect that Caribou Biosciences will post -1.53 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $206,000. Victory Capital Management Inc. acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $2,027,000. New York State Common Retirement Fund acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $414,000. Herold Advisors Inc. acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $60,000. Finally, Deutsche Bank AG acquired a new stake in shares of Caribou Biosciences during the 3rd quarter worth $279,000. 62.86% of the stock is currently owned by hedge funds and other institutional investors.

About Caribou Biosciences (Get Rating)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma.

Featured Stories